These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8983284)

  • 81. Oral ondansetron: an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children.
    Cohen IJ; Zehavi N; Buchwald I; Yaniv Y; Goshen Y; Kaplinsky C; Zaizov R
    Pediatr Hematol Oncol; 1995; 12(1):67-72. PubMed ID: 7703044
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
    Viner CV; Selby PJ; Zulian GB; Gore ME; Butcher ME; Wootton CM; McElwain TJ
    Cancer Chemother Pharmacol; 1990; 25(6):449-53. PubMed ID: 2138064
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Safety of ondansetron loading doses in children with cancer.
    Hasler SB; Hirt A; Ridolfi Luethy A; Leibundgut KK; Ammann RA
    Support Care Cancer; 2008 May; 16(5):469-75. PubMed ID: 17940810
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Use of oral and intravenous ondansetron in patients treated with cisplatin.
    Khoo KS; Ang PT; Soh LT; Au E
    Ann Acad Med Singap; 1993 Nov; 22(6):901-4. PubMed ID: 8129353
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients.
    Sandoval C; Corbi D; Strobino B; Fevzi Ozkaynak M; Tugal O; Jayabose S
    Cancer Invest; 1999; 17(5):309-13. PubMed ID: 10370357
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Ondansetron for the control of dacarbazine-induced emesis.
    Campora E; Chiara S; Aschele C
    Eur J Cancer; 1995 Sep; 31A(10):1720-1. PubMed ID: 7488437
    [No Abstract]   [Full Text] [Related]  

  • 87. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron.
    Beck TM
    Anticancer Drugs; 1995 Apr; 6(2):237-42. PubMed ID: 7540892
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Variation in the use of ondansetron as an antiemetic drug in children treated with chemotherapy.
    Ninane J; Ozkaynak MF; Kurtin P; Siegel SE
    Med Pediatr Oncol; 1995 Jul; 25(1):33-7. PubMed ID: 7753000
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation.
    Nahata MC; Hui LN; Koepke J
    Clin Ther; 1996; 18(3):466-76. PubMed ID: 8829022
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ondansetron in radiation therapy of brain tumor in children.
    Lippens RJ; Broeders GC
    Pediatr Hematol Oncol; 1996; 13(3):247-52. PubMed ID: 8735340
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
    Zoubek A; Kronberger M; Puschmann A; Gadner H
    Anticancer Drugs; 1993 Dec; 4 Suppl 2():17-21. PubMed ID: 8136511
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP).
    Thanacoody HK; Gray A; Dear JW; Coyle J; Sandilands EA; Webb DJ; Lewis S; Eddleston M; Thomas SH; Bateman DN
    BMC Pharmacol Toxicol; 2013 Apr; 14():20. PubMed ID: 23556549
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
    Mondick JT; Johnson BM; Haberer LJ; Sale ME; Adamson PC; Coté CJ; Croop JM; Russo MW; Barrett JS; Hoke JF
    Eur J Clin Pharmacol; 2010 Jan; 66(1):77-86. PubMed ID: 19798490
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy of Ondansetron and Lorazepam in controlling emesis associated with cytotoxic chemotherapy.
    Mughal TI
    Acta Oncol; 1994; 33(5):537-9. PubMed ID: 7917368
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Association between ondansetron use and symptom persistence in children with concussions: A 5P substudy.
    Gravel J; Boutis K; Tang K; Beauchamp MH; Freedman SB; Dubrovsky AS; Gagnon I; Momoli F; Zemek R
    CJEM; 2019 Mar; 21(2):204-210. PubMed ID: 29877168
    [TBL] [Abstract][Full Text] [Related]  

  • 96. When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
    Markman M
    Cancer Invest; 1994; 12(6):654-6. PubMed ID: 7994600
    [No Abstract]   [Full Text] [Related]  

  • 97. Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study.
    Freedman SB; Powell EC; Nava-Ocampo AA; Finkelstein Y
    Paediatr Drugs; 2010 Dec; 12(6):405-10. PubMed ID: 21028919
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats.
    Choudhary DR; Patel VA; Chhalotiya UK; Patel HV; Kundawala AJ
    Curr Drug Deliv; 2013 Dec; 10(6):696-700. PubMed ID: 23755722
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cytotoxic chemotherapy has minimal direct effect on gastric myoelectric activity in children with 5HT(3) antagonist prophylaxis.
    Cheng W; Chan GC; Tam PK
    Med Pediatr Oncol; 2000 Jun; 34(6):421-3. PubMed ID: 10842249
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A randomized study of ondansetron syrup in children: evaluation of taste acceptability and tolerance.
    Stevens R; Votan B; Lane R; Schaison G; Hewitt M; Kohler J; Thyss A
    Pediatr Hematol Oncol; 1996; 13(2):199-202. PubMed ID: 8721040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.